AnswersPublished21 sources
Pumitamig Combination Shows Early Activity in Advanced Lung Cancer
ROSETTA Lung 107 reported a 36.7% confirmed response rate and 6.9 month median progression free survival for pumitamig plus docetaxel.
Published byEdited with GPT-6 LunaImages generated with GPT Image 2
Research answer
Key takeaways
- ROSETTA Lung 107 reported a 36.7% confirmed response rate and 6.9 month median progression free survival for pumitamig plus docetaxel.
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: What did BioNTech and Bristol Myers Squibb report on October 25 about their bispecific PD-L1/VEGF-A antibody pumitamig combined with docetax. Article summary: On October 25, 2026, BioNTech and Bristol Myers Squibb reported encouraging early activity for pumitamig plus docetaxel in ROSETTA Lung-107: a 36.7% confirmed objective response rate and an early median progression-free . Topic tags: general, government, general web, user generated, news. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermar
BioNTech and Bristol Myers Squibb reported early results from ROSETTA Lung-107, a Phase 2 trial of investigational pumitamig plus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed after first-line immunotherapy and chemotherapy. Among 30 patients whose tumors could be evaluated, 36.7% had a confirmed response and 90.0% had disease control. The findings are an early signal—not proof that pumitamig improves outcomes beyond docetaxel alone.6
3
12
What ROSETTA Lung-107 reported
The companies presented the global, open-label study as late-breaking rapid oral abstract LBA76 at the ESMO 2026 congress in Madrid on October 25.6
8 Pumitamig, an investigational PD-L1×VEGF-A bispecific immunomodulator, was given at 1,400 mg every three weeks with docetaxel.
6
3
At the July 10, 2026 data cutoff, 50 patients had received treatment. Median follow-up was 12.2 weeks, and 30 patients were evaluable for tumor response.3
5
Among those 30 patients, the confirmed objective response rate was 36.7%, while the disease control rate was 90.0%. The companies reported responses across PD-L1 expression levels and in both squamous and non-squamous NSCLC; the cited reports do not provide numerical response rates for those subgroups.3
17
In the full group of 50 treated patients, median progression-free survival (PFS)—the time patients lived without their disease worsening—was 6.9 months. The reported six-month PFS rate was 63.3%.18
Safety findings and what remains unclear
Reports summarized pumitamig-related adverse events in 52% of patients, with grade 3 or higher events in 18% and discontinuations in 8%. They also reported no pumitamig-related deaths or dose-limiting toxicities.4
19 These figures should be read in the context of a 50-patient safety population and short median follow-up. The available reports do not provide a reliable bleeding rate for this trial.
3
4
The results do not establish how the combination compares with docetaxel alone or historical docetaxel outcomes. ROSETTA Lung-107 had no control arm, so it cannot isolate pumitamig’s contribution to the responses or PFS observed.10
12 The small number of evaluable patients and brief follow-up also make the findings preliminary.
What the results mean
The response and PFS findings support further study of pumitamig plus docetaxel in this second-line setting, but they do not establish a new standard of care. A randomized comparison would be needed to determine whether adding pumitamig improves outcomes over docetaxel alone.12
16
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "Pumitamig Combination Shows Early Activity in Advanced Lung Cancer"?
ROSETTA Lung 107 reported a 36.7% confirmed response rate and 6.9 month median progression free survival for pumitamig plus docetaxel.